2415160-21-1
Chemical Structure
MD-265
- CAS No.: 2415160-21-1
- Formula:C50H51Cl2FN6O6
- Molecular Weight:921.88
InChIKey: ISQCXAWAHDJCRH-FKDRFZFOSA-N
SMILES: O=C([C@H]1CC[C@@H](CC1)NC([C@@H]2NC3(CCCCC3)[C@]4(C5=CC=C(C=C5NC4=O)Cl)[C@H]2C6=CC=CC(Cl)=C6F)=O)N7CCC(C#CC8=C(C(C9=O)=CC=C8)CN9C(C(N%10)=O)CCC%10=O)CC7
Biological Activity: MD-265 is a PROTAC degrader targeting MDM2, which activates p53 in cancer cells carrying wild-type p53. MD-265 induces MDM2 degradation by recruiting the CRL4-CRBN ligase complex via the ubiquitination and proteasomal degradation pathway. MD-265 upregulates p53 target genes, induces apoptosis, reduces Mcl-1 levels, increases caspase-3 cleavage, and inhibits colony formation of wild-type p53 leukemia stem cells. MD-265 can be used in research related to leukemia and acute myeloid leukemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MD-265 | 99.31% | MD-265 is a PROTAC degrader targeting MDM2, which activates p53 in cancer cells carrying wild-type p53. MD-265 induces MDM2 degradation by recruiting the CRL4-CRBN ligase complex via the ubiquitination and proteasomal degradation pathway. MD-265 upregulates p53 target genes, induces apoptosis, reduces Mcl-1 levels, increases caspase-3 cleavage, and inhibits colony formation of wild-type p53 leukemia stem cells. MD-265 can be used in research related to leukemia and acute myeloid leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Aguilar A, et al. Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia. Journal of medicinal chemistry. 2024 Nov 14;67(21):19503-19518. [Content Brief]
- [2]. Kandarpa M, et al. Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models. Leukemia. 2026 May;40(5):918-924. [Content Brief]
Keywords
